Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · Real-Time Price · USD
79.47
+2.66 (3.46%)
At close: Oct 16, 2025, 4:00 PM EDT
78.00
-1.47 (-1.85%)
Pre-market: Oct 17, 2025, 8:02 AM EDT
Corcept Therapeutics Revenue
Corcept Therapeutics had revenue of $194.43M in the quarter ending June 30, 2025, with 18.70% growth. This brings the company's revenue in the last twelve months to $716.08M, up 25.71% year-over-year. In the year 2024, Corcept Therapeutics had annual revenue of $675.04M with 39.94% growth.
Revenue (ttm)
$716.08M
Revenue Growth
+25.71%
P/S Ratio
11.52
Revenue / Employee
$1,432,160
Employees
500
Market Cap
8.37B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 675.04M | 192.67M | 39.94% |
Dec 31, 2023 | 482.38M | 80.52M | 20.04% |
Dec 31, 2022 | 401.86M | 35.88M | 9.80% |
Dec 31, 2021 | 365.98M | 12.10M | 3.42% |
Dec 31, 2020 | 353.87M | 47.39M | 15.46% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CORT News
- 1 day ago - Corcept Transition To New Specialty Pharmacy Well Underway - Seeking Alpha
- 3 days ago - Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire
- 15 days ago - Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics - Business Wire
- 18 days ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga
- 20 days ago - Corcept Primed For An Upside EPS Surprise - Seeking Alpha
- 24 days ago - Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025 - Business Wire
- 4 weeks ago - 11 fast-growing small-cap stocks that could get a boost from the Fed's next move - Market Watch
- 5 weeks ago - FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer - Business Wire